Skip to main content

A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting · Phase 4 · NCT05433584

Conditions: Type 2 Diabetes

At a glance

Research payments reported, 2025
$1.8M
U.S. investigators named
34
Sites paid
28
Planned or actual enrollment
780

About the trial

Sponsor
Eli Lilly and Company
Tested
Tirzepatide (drug), Antihyperglycemic medication (drug)
Dates
Started 2022-08-01; completion 2027-11
Results posted
Not yet

This study aims to investigate the efficacy and safety of tirzepatide in participants with type 2 diabetes (T2D) compared to other existing treatment options when treatment is initiated early.

From ClinicalTrials.gov, last updated 2025-12-12. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Eli Lilly and Company reported $1.8M in research payments for this study in 2025 (48 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Velocity Clinical Research Inc $278,891
  • Sky Clinical Research Network Group $277,860
  • Dorado Medical Complex Inc $192,516
  • South Florida Wellness and Clinical Resear $143,342
  • Gcm Medical Group Psc $136,922
  • Corvallis Clinic PC $101,281
  • San Fernando Valley Health Institute LLC $82,646
  • Lucas Research Inc $63,484
  • Studymetrix Research LLC $51,683
  • Escuela De Medicina San Juan Bautista $47,608
  • Iowa Diabetes and Endocrinology Rsrch Cntr $47,213
  • Tribe Clinical Research LLC $42,449
  • Center for Advanced Research & Education LLC $35,517
  • Clinical Research Philadelphia LLC $33,882
  • Clinvest Research LLC $32,393
  • Clinical Trials Research Inc $32,362
  • Emory University Hospital, GA $25,538
  • Alliance for Multispecialty Research Lls $23,169
  • Excel Medical Clinical Trials, LLC $21,436
  • Western University of Health Sciences $20,487
  • Qualmedica Research LLC $19,601
  • Preferred Primary Care Physicians Inc $14,951
  • Neccr Prima Care Research LLC $13,422
  • Cahaba Research $12,463
  • Cleveland Clinic, OH $942
  • Andrew J Lewin Med DBA National Rsrch Institute $906
  • Clinical Research of Philadelphia LLC $253
  • Mountain View Clinical Research Inc $192

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.